POS0077-HPR ENHANCING CURRENT GUIDANCE FOR PSORIATIC ARTHRITIS AND ITS COMORBIDITIES: RECOMMENDATIONS FROM AN EXPERT CONSENSUS PANEL OF HEALTHCARE PROFESSIONALS IN THE UK

Background Psoriatic arthritis (PsA) is a chronic inflammatory occurring in 20–30% of patients with psoriasis. [1] Timely diagnosis important because untreated PsA can lead to irreversible joint damage and functional disability. [2] While existing national international guidelines, such as those provided by EULAR, BSR, ACR/National Psoriasis Foundation GRAPPA, cover wide range aspects pharmacological management PsA, gaps have been identified relating the application guidance clinical practice, ongoing non-pharmacological management, quality care benchmarking, often related lack evidence. In response, an expert UK consensus group aimed enhance current guidance. Objectives To develop evidence- consensus-based set recommendations for routine practice that adds value suggests minimum best standards day-to-day provides practical strategies achieve these standards, aim supporting clinicians. Methods A steering committee (SC) was formed 12 experts fields rheumatology, dermatology primary care. At initial meeting, themes were discussed agreed (PsA diagnosis, disease assessment, comorbidities, management) questions drafted. targeted literature review PubMed Embase following PICO framework conducted gather scientific evidence selection questions, while others be more appropriate answer using experience. second drafted response covering guidelines. For next stage, extended faculty recruited including rheumatologists (32), dermatologists (6), representatives (3), specialist nurses (5), academics (12) members Brit-PACT patient [6]. online voting platform, SC entered agreement score each recommendation. Consensus achieved when 75% respondents 7–9 on 9-point scale. Results The 34 statements 15 management. theme focussed identify early refer appropriately, assessment diagnostic indicators, use screening tools. imaging support referral time frames also covered detail. Recommendations centred holistic consideration activity, impairment impact from perspective, well how implement shared decision-making. Specific measurements performed at clinic visits included. made specific high-impact conditions, depression obesity, implications therapy. Management (which excluded therapies extant guidelines) multidisciplinary team working, implementation lifestyle modifications, treat-to-target built upon parameters greatest importance individual patients. corticosteroids recommended minimised where feasible. Conclusion This programme critical areas beyond therapy could enhanced greater relevance work will developed into resource healthcare professionals PsA. References [1]Mulder M et al. Arthritis Res Ther. 2021;23(1):168 [2]Haroon Ann Rheum Dis. 2015;74(6):1045–50 Acknowledgements: NIL. Disclosure Interests Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer, UCB, Consultant of: Bristol Myers Squibb, Moonlake, Grant/research from: Marwan Bukhari Jannssen, Merck, Antoni Chan Ernest Choy Boehringer Ingelheim, Chugai Pharma, Fresenius Kai, Hospira, MSD, Regeneron, Roche, Sanofi-Aventis, Sanofi-Genzyme, Bio-Cancer, Sanofi, James Galloway Nicola Gullick AstraZeneca, Alison Kent Merck-Sharp & Dohme, Sanofi Genzyme, Savage Almirall, Celltrion, Galderma, Janssen-Cilag, Leo, MSD Pfizer Stefan Siebert Institutional research Amgen (previously Celgene), William Tillett Ono Natasha Wood Philip G Conaghan Biosplice, Genascence, Stryker, UCB.